Navigation Links
Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

WOODCLIFF LAKE, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the second quarter ended June 27, 2009.

For the second quarter ended June 27, 2009, Par reported total revenues of $404.0 million and net income of $23.8 million, or $0.71 per diluted share, which included a one-time gain related to the acquisition of certain assets of MDRNA's Hauppauge, NY facility. Adjusting for this item, earnings per diluted share were $0.65 for the three month period ended June 27, 2009. This is compared to reported revenues of $112.9 million and a net loss of $21.2 million, or $0.64 loss per diluted share for the same period in 2008, which included a one-time development milestone payment to a partner. Adjusting for this item, loss per diluted share was $0.61 for the three month period ended June 28, 2008.

For the six months ended June 27, 2009, total revenue was $608.0 million with net income of $39.9 million, or $1.18 per diluted share. This is compared to total revenues of $267.9 million and a net loss of $19.8 million, or $0.60 per diluted share in the same period of 2008.

Second Quarter Highlights

Key Product Sales (Net sales comparisons at the product level are to first quarter 2009)

  • Metoprolol: For the quarter ended June 27, 2009, net sales of metoprolol succinate reached $306 million, an increase of 173% from the first quarter 2009. The increase was driven by market exclusivity and additional product supply which led to increased volume and price. Par remained the exclusive supplier of metoprolol succinate through the second quarter. Par is the authorized generic for all strengths of AstraZeneca's Toprol(R) XL.

  • Sumatriptan: Net sales of sumatriptan injection were $21.8 million for the quarter ended June 27, 2009 compared to $16.0 million in the first quarter. The increase was principally due to trade buying patterns, which included the release of backorders. Par remained the exclusive supplier of generic Imitrex(R) 4mg and 6mg starter kits and 4mg prefilled cartridges and had one competitor in the 6mg prefilled cartridges throughout the second quarter.

  • Meclizine: Net sales for the three months ended June 27, 2009 were $8.9 million compared to $9.8 million in the first quarter of 2009. The decrease was due primarily to trade buying patterns. Par was the exclusive supplier of meclizine in the first half of 2009.

  • Dronabinol: Net sales for the second quarter 2009 were $5.5 million compared to $7.0 million in the first quarter. The decrease was due to competitive pricing pressures.

  • Other generic products: For the second quarter 2009, net sales from all other generic products were $39.6 million compared to $43.0 million in the first quarter. The decrease primarily reflects the discontinuation of fluticasone and a decline in volume and price of certain products, including ibuprofen, due to continued competition in the market, tempered by an increase in volume of certain products such as tramadol APAP and fluoxetine HCl, as well as the launch of risperidone ODT in June 2009.

  • Megace(R) ES: Net sales were $17.1 million for the three months ended June 27, 2009 compared to $13.5 million in the first quarter. The increase in net sales was due to the increase in prescription demand and the return to normal trade buying patterns.

  • Nascobal(R) B12 Nasal Spray: Net sales were $2.2 million for the three months ended June 27, 2009. Strativa Pharmaceutical purchased Nascobal from QOL Medical, LLC on March 31, 2009 and re-launched the product on June 15, 2009.

Total net revenues for the three months ended June 27, 2009, were $404 million, up $291 million, or nearly 258%, from the year ago period, principally driven by the lack of competition in metoprolol succinate and meclizine, as well as the launches of sumatriptan injection and dronabinol in the second half of 2008.

Gross margin for the second quarter 2009 was $86.4 million, or 21.4% of total revenue, an increase of $61.3 million from the comparable period in 2008. Total generic gross margin in the second quarter 2009 was $70.7 million, or 18.5% of total generic revenue, compared to $9.2 million, or 9.9% of total generic revenue in the second quarter 2008. This increase is due primarily to higher sales of metoprolol and meclizine and the launches of sumatriptan and dronabinol. These four products contributed $52.5 million of gross margin, or 15.3% of such generic revenue. Gross margin of all other generic products was approximately $18.2 million, or 46% of other generic revenue. This compares to $5.4 million, or 10.0% of other generic revenue, in the second quarter of 2008. The increase in gross margin percentage was due to the trimming of the generic product line as part of the resizing of Par's generic division in the fourth quarter of 2008. Strativa's gross margin of $15.7 million, or 72% of total Strativa revenue, decreased compared to the second quarter of 2008 due to lower sales of Megace(R) ES.

Research and development (R&D) expenses decreased 63% to $5.9 million in the second quarter of 2009 compared to the second quarter 2008 due primarily to the resizing of the generic division, which included a headcount reduction and lower development and biostudy costs.

Selling, general and administrative (SG&A) expenses for the second quarter 2009 increased to $44.1 million compared to $36.7 million in the second quarter 2008. The increase reflects an increase of $6.8 million related to on-going expenditures supporting Strativa sales and marketing, driven primarily by an increase in the field force and other activities in preparation for the re-launch of Nascobal B12 Nasal Spray, as well as development costs of other products.

Cash and cash equivalents and marketable securities aggregate balance as of June 27, 2009, was $202.3 million and reflects significant one-time cash outflows related to the purchase of Nascobal B12 Nasal Spray (approximately $55 million), the year-to-date repurchase of $13.8 million face value of Par's convertible debt at a discount and, as previously reported in the first quarter, the settlement of litigation with Pentech (approximately $66 million).

Face Value of Convertible Debt as of June 27, 2009, was $128.2 million. An additional $35.5 million in convertible debt was repurchased subsequent to the balance sheet date at a discount. The face value of convertible debt currently stands at $92.7 million and matures on September 30, 2010, unless earlier converted or repurchased.

Product and Pipeline Update

Strativa's New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS) has been accepted by the FDA for review. Pursuant to Prescription Drug User Fee Act (PDUFA), Strativa expects the FDA will complete its review by February 7, 2010. If approved, ondansetron ODFS could launch by mid-2010.

BioAlliance Pharma, Strativa's development partner for miconazole, mucoadhesive bucccal tablets (MBT), which is marketed under the brand name Loramyc(R) in Europe, submitted its NDA to the FDA. Pursuant to PDUFA, BioAlliance expects the FDA will complete its review by second quarter 2010. If approved, Strativa could launch the product in the second half of 2010.

Par successfully launched five strengths of risperidone ODT, a generic version of Risperdal(R) M-TAB, during the second quarter, and was the exclusive supplier of .25mg, 3mg and 4mg strengths of the product during the period. Risperdal M-TAB had $108.0 million in annual sales in 2008 according to IMS Health.

Par also launched calcitonin-salmon nasal spray, the generic version of Miacalcin(R), during the quarter. Annual U.S. sales of Miacalcin were approximately $104 million in 2008, according to IMS Health.

Par currently has approximately 37 ANDAs pending with the FDA, 14 of which Par believes to be first-to-file and/or first-to-market opportunities with a brand value of approximately $5.9 billion.

Conference Call

Par has scheduled a conference call for Tuesday, August 4 at 9:00 am EDT to discuss results for the second quarter of 2009. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at and will be available for two weeks. The dial-in number is 866-788-0539 for domestic callers and 857-350-1677 for international callers. The access number is 40463383. A replay of the conference call will be available commencing approximately one hour after the call. The replay dial-in number is 888-286-8010 for domestic callers and 617-801-6888 for international callers. The access number is 95297063.

Non-GAAP Measures

Par believes it prepared its condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q. In an effort to provide investors with additional information regarding Par's results and to provide a meaningful period-over-period comparison of Par's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission. The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in an attached schedule. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating Par's underlying business performance. Management uses the non-GAAP financial measures to evaluate Par's financial performance against internal budgets and targets. In addition, management internally reviews Par's results excluding the impact of certain items, as it believes that these non-GAAP financial measures are useful for evaluating Par's core operating results and facilitating comparison across reporting periods. Importantly, Par believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures. Par's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

                        PAR PHARMACEUTICAL COMPANIES, INC.
                        (In Thousands, Except Share Data)

                                                    June 27,    December 31,
                                                      2009          2008
                                                      ----          ----
    Current assets:
        Cash and cash equivalents                   $139,359      $170,629
        Available for sale marketable debt and
         equity securities                            62,980        93,097
        Accounts receivable, net                     261,950        83,408
        Inventories                                   55,072        42,504
        Prepaid expenses and other current
         assets                                       15,581        20,040
        Deferred income tax assets                    37,474        53,060
        Income taxes receivable                       22,257        35,397
                                                      ------        ------
        Total current assets                         594,673       498,135

    Property, plant and equipment, at cost
     less accumulated depreciation and
     amortization                                     79,271        79,439
    Available for sale marketable debt and
     equity securities                                 1,150         1,949
    Intangible assets, net                            78,252        35,208
    Goodwill                                          63,729        63,729
    Deferred financing costs and other
     assets                                              828         1,159
    Non-current deferred income tax assets,
     net                                              67,211        68,618
                                                      ------        ------
    Total assets                                    $885,114      $748,237
                                                    ========      ========

    Current liabilities:
        Current portion of long-term debt                 $-      $130,141
        Accounts payable                              38,622        22,879
        Payables due to distribution agreement
         partners                                    177,103        91,451
        Accrued salaries and employee benefits        14,550        11,850
        Accrued expenses and other current
         liabilities                                  37,466        38,352
                                                      ------        ------
        Total current liabilities                    267,741       294,673

    Long-term debt, less current portion             120,038             -
    Other long-term liabilities                       41,259        41,581
    Commitments and contingencies                          -             -

    Stockholders' equity
        Common Stock, par value $0.01 per share,
         authorized 90,000,000 shares; issued
             37,560,564 and 37,392,469 shares            375           374
        Additional paid-in capital                   325,173       319,976
        Retained earnings                            199,360       159,470
        Accumulated other comprehensive gain             816           122
        Treasury stock, at cost 2,792,963 and
         2,716,010 shares                            (69,648)      (67,959)
                                                     -------       -------
        Total stockholders' equity                   456,076       411,983
                                                     -------       -------
    Total liabilities and stockholders'
     equity                                         $885,114      $748,237
                                                    ========      ========

                        PAR PHARMACEUTICAL COMPANIES, INC.
                       (In Thousands, Except Per Share Data)

                                    Three Months Ended     Six Months Ended
                                    ------------------     ----------------
                                  June 27,      June 28,  June 27,   June 28,
                                   2009           2008      2009       2008
                                   ----           ----      ----       ----

        Net product sales        $400,149       $108,289  $600,372   $259,526
        Other product related
         revenues                   3,852          4,648     7,664      8,339
                                    -----          -----     -----      -----
    Total revenues                404,001        112,937   608,036    267,865
    Cost of goods sold            317,593         87,829   457,559    193,236
                                  -------         ------   -------    -------
        Gross margin               86,408         25,108   150,477     74,629
    Operating expenses:
        Research and development    5,937         15,955    13,109     33,113
        Selling, general and
         administrative            44,117         36,690    77,077     68,037
        Settlements and loss
         contingencies, net            61              -    (3,315)         -
        Restructuring costs            81              -     1,482          -
                                       --              -     -----          -
    Total operating expenses       50,196         52,645    88,353    101,150
                                   ------         ------    ------    -------
    Gain on sale of product
     rights and other                 265            500     1,365      2,125
                                      ---            ---     -----      -----
    Operating income (loss)        36,477        (27,037)   63,489    (24,396)
    Gain on bargain purchase        3,021              -     3,021          -
    Gain on extinguishment of
     senior subordinated
     convertible notes                504              -       749          -
    Equity in loss of joint
     venture                            -           (310)        -       (330)
    Loss on marketable
     securities and other
     investments, net                   -           (433)      (55)      (433)
    Interest income                   667          2,129     1,824      5,143
    Interest expense               (2,595)        (3,544)   (5,162)    (7,054)
                                  -------        -------   -------    -------
    Income (loss) from
     continuing operations
     before provision
     (benefit) for income
     taxes                         38,074        (29,195)   63,866    (27,070)
    Provision (benefit) for
     income taxes                  14,087         (8,236)   23,624     (7,495)
                                   ------        -------    ------    -------
    Income (loss) from
     continuing operations         23,987        (20,959)   40,242    (19,575)
    Discontinued operations:
    Gain from discontinued
     operations                         -              -         -        505
    Provision for income taxes        176            268       352        713
                                      ---            ---       ---        ---
    Gain (loss) from
     discontinued operations         (176)          (268)     (352)      (208)
                                     ----           ----      ----       ----
    Net income (loss)             $23,811       ($21,227)  $39,890   ($19,783)
                                  =======       ========   =======   ========

    Basic earnings (loss) per
     share of common stock:
    Income (loss) from
     continuing operations          $0.71         ($0.63)    $1.20     ($0.59)
    Gain (loss) from
     discontinued operations         0.00          (0.01)    (0.01)     (0.01)
                                     ----          -----     -----      -----
    Net income (loss)               $0.71         ($0.64)    $1.19     ($0.60)
                                    =====        =======     =====    =======

    Diluted earnings (loss)
     per share of common stock:
    Income (loss) from
     continuing operations          $0.71         ($0.63)    $1.19     ($0.59)
    Gain (loss) from
     discontinued operations         0.00          (0.01)    (0.01)     (0.01)
                                     ----          -----     -----      -----
    Net income (loss)               $0.71         ($0.64)    $1.18     ($0.60)
                                    =====        =======     =====    =======

    Weighted average number of
     common shares
      Basic                        33,630         33,304    33,616     33,262
                                   ======         ======    ======     ======
      Diluted                      33,771         33,304    33,772     33,262
                                   ======         ======    ======     ======

     Reconciliation Between Reported (GAAP) and Adjusted Net Income (Loss)
                     (In thousands, except per share data)

                                                       Three Months Ended
                                                    June 27,         June 28,
                                                      2009             2008
                                                      ----             ----

    Reported Net Income (Loss)                      $23,811         ($21,227)
    Development Milestone Payments                        -            1,250
    Gain on Bargain Purchase                         (3,021)               -
    Restructuring Costs                                  81                -
    Estimated Tax on Adjustments                      1,094             (475)
                                                      -----             ----
    Adjusted Net Income (Loss) (non-GAAP measure)   $21,965         ($20,452)
                                                    =======         ========

    Diluted Earnings (Loss) Per Share:
          Reported                                    $0.71           ($0.64)
                                                      =====           ======
          Adjusted (non-GAAP measure)                 $0.65           ($0.61)
                                                      =====           ======

                                                        Six Months Ended
                                                     June 27,         June 28,
                                                       2009             2008
                                                       ----             ----

    Reported Net Income (Loss)                      $39,890         ($19,783)
    Change in Estimate Related to Final Pentech
     Settlement                                      (3,412)               -
    Development Milestone Payments                    1,000            6,250
    Gain on Bargain Purchase                         (3,021)               -
    Restructuring Costs                               1,482                -
    Estimated Tax on Adjustments                      1,462           (2,375)
                                                      -----           ------
    Adjusted Net Income (Loss) (non-GAAP measure)   $37,401         ($15,908)
                                                    =======         ========

    Diluted Earnings (Loss) Per Share:
          Reported                                    $1.18           ($0.60)
                                                      =====           ======
           Adjusted (non-GAAP measure)                $1.11           ($0.48)
                                                      =====           ======

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
2. Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
3. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
7. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
8. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
9. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
10. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
11. Growth in Personalized Medicine to Drive Alliances Between Diagnostics and Pharmaceutical Industries, According to PricewaterhouseCoopers
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology: